Cornercap Investment Counsel Inc. Raises Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Cornercap Investment Counsel Inc. lifted its stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) by 24.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,673 shares of the company’s stock after purchasing an additional 3,294 shares during the period. Cornercap Investment Counsel Inc.’s holdings in Deciphera Pharmaceuticals were worth $269,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its holdings in Deciphera Pharmaceuticals by 96.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock worth $26,000 after acquiring an additional 997 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Deciphera Pharmaceuticals in the first quarter worth about $57,000. Compass Wealth Management LLC bought a new position in Deciphera Pharmaceuticals during the fourth quarter valued at approximately $70,000. Advisor Group Holdings Inc. boosted its stake in Deciphera Pharmaceuticals by 78.0% during the fourth quarter. Advisor Group Holdings Inc. now owns 4,331 shares of the company’s stock valued at $71,000 after buying an additional 1,898 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Deciphera Pharmaceuticals by 144.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,817 shares of the company’s stock valued at $96,000 after buying an additional 4,024 shares in the last quarter. 70.96% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Wednesday, March 20th. Stifel Nicolaus upped their target price on shares of Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $23.00.

Deciphera Pharmaceuticals Stock Down 0.8 %

Shares of Deciphera Pharmaceuticals stock opened at $14.72 on Thursday. The stock’s fifty day moving average is $15.70 and its two-hundred day moving average is $14.21. Deciphera Pharmaceuticals, Inc. has a 52 week low of $9.90 and a 52 week high of $17.73. The company has a market capitalization of $1.19 billion, a PE ratio of -6.43 and a beta of 0.39.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.04. The firm had revenue of $48.30 million for the quarter, compared to analysts’ expectations of $45.93 million. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative return on equity of 49.44%. The business’s revenue for the quarter was up 32.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.60) earnings per share. As a group, research analysts anticipate that Deciphera Pharmaceuticals, Inc. will post -2.16 earnings per share for the current year.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.